CA3099042A1 - Mesenchymal stromal cell exosome -treated monocytes and uses thereof - Google Patents

Mesenchymal stromal cell exosome -treated monocytes and uses thereof Download PDF

Info

Publication number
CA3099042A1
CA3099042A1 CA3099042A CA3099042A CA3099042A1 CA 3099042 A1 CA3099042 A1 CA 3099042A1 CA 3099042 A CA3099042 A CA 3099042A CA 3099042 A CA3099042 A CA 3099042A CA 3099042 A1 CA3099042 A1 CA 3099042A1
Authority
CA
Canada
Prior art keywords
monocyte
isolated
msc
treated
exosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099042A
Other languages
English (en)
French (fr)
Inventor
Stella KOUREMBANAS
S. Alexander Mitsialis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CA3099042A1 publication Critical patent/CA3099042A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3099042A 2018-05-09 2019-05-09 Mesenchymal stromal cell exosome -treated monocytes and uses thereof Pending CA3099042A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669324P 2018-05-09 2018-05-09
US62/669,324 2018-05-09
PCT/US2019/031467 WO2019217646A1 (en) 2018-05-09 2019-05-09 Mesenchymal stromal cell exosome -treated monocytes and uses thereof

Publications (1)

Publication Number Publication Date
CA3099042A1 true CA3099042A1 (en) 2019-11-14

Family

ID=68467835

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099042A Pending CA3099042A1 (en) 2018-05-09 2019-05-09 Mesenchymal stromal cell exosome -treated monocytes and uses thereof

Country Status (6)

Country Link
US (1) US20210213056A1 (https=)
EP (1) EP3790560A4 (https=)
JP (2) JP2021522824A (https=)
CN (1) CN112469423A (https=)
CA (1) CA3099042A1 (https=)
WO (1) WO2019217646A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2949083C (en) 2014-05-18 2023-10-10 Children's Medical Center Corporation Methods and compositions relating to exosomes
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
CN112334190B (zh) 2018-04-30 2024-09-20 儿童医学中心公司 间充质基质细胞外排体及其用途
WO2021145395A1 (ja) * 2020-01-15 2021-07-22 富士フイルム和光純薬株式会社 抗線維化剤、及び抗線維化作用を有する細胞外小胞の製造方法
WO2021145396A1 (ja) 2020-01-15 2021-07-22 富士フイルム和光純薬株式会社 血管新生剤、及び血管新生作用を有する細胞外小胞の製造方法
US20230248773A1 (en) 2020-07-09 2023-08-10 Exo Biologics Sa Extracellular Vesicles and Compositions Thereof
US20220127579A1 (en) * 2020-10-22 2022-04-28 Wisconsin Alumni Research Foundation Use of Toll-Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury
CN116999463A (zh) * 2022-04-27 2023-11-07 中山大学附属第三医院 一种间充质干细胞来源外泌体在制备治疗间质性膀胱炎药物中的应用
CN115475250B (zh) * 2022-05-26 2024-03-26 南京鼓楼医院 一种靶向肝星状细胞并抑制其激活的载药外泌体及其制备和应用
TW202417616A (zh) * 2022-09-02 2024-05-01 財團法人醫藥工業技術發展中心 包含間質幹細胞的組成物在緩解骨髓纖維化上的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944361A1 (en) * 2007-01-11 2008-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for expanding monocytes
US20130273011A1 (en) * 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
US10166254B2 (en) * 2014-09-19 2019-01-01 Wisconsin Alumni Research Foundation Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
WO2018183825A1 (en) * 2017-03-31 2018-10-04 Wisconsin Alumni Research Foundation Generation of therapeutic cells using extracellular components of target organs
US10876753B2 (en) * 2018-02-12 2020-12-29 Watsco Ventures Llc Integrated sensor and service port for HVAC equipment or HVAC system

Also Published As

Publication number Publication date
JP2024163978A (ja) 2024-11-26
WO2019217646A1 (en) 2019-11-14
EP3790560A4 (en) 2022-03-30
EP3790560A1 (en) 2021-03-17
WO2019217646A8 (en) 2020-01-23
JP2021522824A (ja) 2021-09-02
US20210213056A1 (en) 2021-07-15
CN112469423A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
US20210213056A1 (en) Mesenchymal stromal cell exosome-treated monocytes and uses thereof
Liu et al. Mitochondrial transfer/transplantation: an emerging therapeutic approach for multiple diseases
Kerkis et al. Early transplantation of human immature dental pulp stem cells from baby teeth to golden retriever muscular dystrophy (GRMD) dogs: local or systemic?
US20220023347A9 (en) Purified mesenchymal stem cell exosomes and uses thereof
Wu et al. Cardiac potential of stem cells from whole human umbilical cord tissue
US20140220053A1 (en) Microvesicles isolated from mesenchymal stem cells for use as immunosuppressive agents
US12521418B2 (en) Mesenchymal stromal cell exosomes and uses thereof
US20210315940A1 (en) Use of mesenchymal stromal cell exosomes in antenatal therapy
JP6722599B2 (ja) 全身性炎症反応症候群の治療のための間葉系間質細胞
US20140105871A1 (en) Use Of Mesenchymal Stem Cells For The Improvement Of Affective And Cognitive Function
JP5809068B2 (ja) 免疫抑制−関連疾患の治療
JPWO2017204231A1 (ja) 臍帯由来細胞を含む脳障害の治療剤
Li et al. Renal and bone marrow cells fuse after renal ischemic injury
Li et al. Therapeutic potential of urine-derived stem cells in renal regeneration following acute kidney injury: A comparative analysis with mesenchymal stem cells
JP6722598B2 (ja) 関節リウマチ治療のための間葉系間質細胞
Abd El-Haleem et al. Bone marrow–derived mesenchymal stem cells ameliorate parotid injury in ovariectomized rats
EP3214171A1 (en) Placenta-derived cells excreting c3 or c1r complement and composition containing same
WO2025049883A1 (en) Compositions and methods for treating a disease or disorder associated with senescence
JP7072777B2 (ja) 慢性腎障害治療のための多能性幹細胞
KR102390909B1 (ko) 미토콘드리아를 포함하는 허혈성 질환 예방 또는 치료용 조성물
WO2018003997A1 (ja) 臓器線維症の予防または治療剤
WO2017199976A1 (ja) 多能性幹細胞による周産期脳障害の改善及び治療
CN119162082A (zh) 诱导成纤维细胞直接重编程为肝样细胞制备肝系外囊泡/凋亡囊泡的方法及其应用
Class et al. Patent application title: MESENCHYMAL STROMAL CELL EXOSOMES AND USES THEREOF
WO2022102784A1 (ja) 筋肉量の低下抑制に用いる細胞調製物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240418

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251121